Copyright
©The Author(s) 2018.
World J Cardiol. Feb 26, 2018; 10(2): 6-14
Published online Feb 26, 2018. doi: 10.4330/wjc.v10.i2.6
Published online Feb 26, 2018. doi: 10.4330/wjc.v10.i2.6
Conditions | MCV | RDW |
Chronic diseases anemia | ↓ | N |
Heterozygous thalassemia | ↓ | N |
Iron deficiency | ↓ | ↑ |
β-thalassemia | ↓ | ↑ |
Sickle cell trait | ↓ | N |
Haemolytic anemia | N/↓ | ↑ |
Hereditary spherocytosis | N/↓ | ↑ |
Sickle cell disease | N | ↑ |
Haemorrhage | N | N |
Blood transfusions | N | ↑ |
Chronic liver disease | N/↑ | ↑ |
Aplastic anemia | ↑ | N |
Folate deficiency | ↑ | ↑ |
Vitamin B12 deficiency | ↑ | ↑ |
Myelodysplastic syndrome | ↑ | ↑ |
Ref. | Variable | Outcome measure | Baseline RDW |
Huang et al[28], 2014 | 1% increase in RDW value | Risk of future death in patients with HF | HR, 1.10 (95%CI: 1.07-1.13) |
Risk of hospitalization in patients with HF | HR, 1.09 (95%CI: 1.03-1.16) | ||
Shao et al[29], 2015 | 1% increase in RDW value | Risk of future MACE in patients with HF | HR, 1.19 (95%CI: 1.08-1.30) |
Risk of future death in patients with HF | HR, 1.12 (95%CI: 1.08-1.16) | ||
Hou et al[30], 2017 | 1% increase in RDW value | General risk of HF | HR, 1.11 (95%CI: 1.05-1.17) |
HR, 1.11 (95%CI: 1.04-1.14) |
Ref. | Study design | Outcome measure | Variable | Baseline RDW | Longitudinal RDW change |
Cauthen et al[31], 2012 | Retrospective, 6159 patients with chronic HF | 1-year all-cause mortality | 1% increase in RDW at diagnosis or during 1 year of follow-up | RR, 1.09 (95%CI: 1.01-1.17) | RR, 1.21 (95%CI: 1.08-1.34) |
Makhoul et al[32], 2013 | Prospective, 614 patients with acute decompensated HF followed-up during hospital stay | All-cause mortality during hospital stay | 1% increase in RDW value at admission or during hospital stay | HR, 1.15 (95%CI: 1.08-1.21) | HR, 1.23 (95%CI: 1.09-1.38) |
Núñez et al[33], 2014 | Prospective, 1702 patients with HF followed-up for 18 mo | All-cause mortality during follow-up | RDW ≥ 15% at admission or during follow-up | Anemic patients: HR, 1.04 (95%CI: 1.00-1.07)Non-anemic patients: HR, 1.11 (95%CI: 1.05-1.19) | Anemic patients: HR, 1.08 (95%CI: 1.04-1.13)Non-anemic patients: HR, 1.31 (95%CI: 1.22-1.42) |
Ferreira et al[35], 2016 | Retrospective, 502 patients with acute decompensated HF | Hospitalization for acute decompensated HF or 180-d cardiovascular death | RDW ≥ 15% at admission and delta RDW > 0 at discharge | OR, 1.29 (95%CI: 0.71-2.33) | OR, 2.47 (95%CI: 1.35-4.51) |
Muhlestein et al[34], 2016 | Prospective, 6414 patients with HF followed-up during hospital stay | 30-d all-cause mortality | 1% increase in RDW value at admission and during hospital stay | HR, 1.09 (95%CI: 1.07-1.12) | HR, 1.09 (95%CI: 1.03-1.16) |
Uemura et al[36], 2016 | Prospective, 229 patients with acute decompensated HF followed-up followed for 692 d | All-cause mortality during follow-up | RDW ≥ 14.5% at admission and positive change of RDW at discharge | HR, 1.08 (95%CI: 0.99-1.19) | HR, 1.19 (95%CI: 1.01-1.41) |
Turcato et al[37], 2017 | Retrospective, 588 patients with acute decompensated HF | 30-d all caused mortality | ΔRDW > 0.4% at 48 and 96 h | - | OR, 3.04 (95%CI: 1.56-5.94) and 3.65 (95%CI: 2.02-6.15) |
- Citation: Lippi G, Turcato G, Cervellin G, Sanchis-Gomar F. Red blood cell distribution width in heart failure: A narrative review. World J Cardiol 2018; 10(2): 6-14
- URL: https://www.wjgnet.com/1949-8462/full/v10/i2/6.htm
- DOI: https://dx.doi.org/10.4330/wjc.v10.i2.6